Clinical trials: Hypertension,Essential
Hypertension,Essential
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or…
- Trial name
- NCT05413057
- Where
- South Korea
- Volunteers
- 20,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744439
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
CKD-828 Telmisartan Non-Responder Trial
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately…
- Trial name
- NCT01426100
- Testing
- CKD-828 40/2.5mg, CKD-828 40/5mg, Telmisartan 80mg
- Where
- 18 sites in South Korea
- Volunteers
- 183 people
- Sponsor
- Chong Kun Dang Pharmaceutical
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
- Trial name
- NCT01615198
- Testing
- Olmesartan, LCZ696
- Where
- 79 sites in China, Hong Kong and 5 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by candesartan cilexetil monotherapy.
- Trial name
- NCT02368652
- Testing
- Candesartan cilexetil 16mg, Amlodipine 10mg, Candesartan cilexetil 16mg
- Where
- 19 sites in South Korea
- Volunteers
- 181 people
- Sponsor
- HK inno.N Corporation
Essential Hypertension
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure.
- Trial name
- NCT01122251
- Testing
- Lercanidipine + Valsartan, Lercanidipine or Valsartan
- Where
- 2 sites in South Korea
- Volunteers
- 441 people
- Sponsor
- LG Life Sciences
Essential Hypertension
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.
The purpose of this study was to evaluate the efficacy and the safety of a fixed-dose combination in capsule of Amlodipine 5mg/ Bisoprolol fumarate 5mg/ Perindopril arginine 5mg, and free monotherapy at the same dose in patients…
- Trial name
- NCT05288400
- Testing
- Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg, Norvasc 5mg tablet, Concor 5mg tablet
- Where
- 15 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Servier
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT07421414
- Testing
- BR1015-A, BR1015-3, BR1015-2
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately…
- Trial name
- NCT06416865
- Testing
- AJU-C52L, AJU-C52, C52R1L, C52R1M
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- AJU Pharm Co., Ltd.
Essential Hypertension, Hepatic Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers
- Trial name
- NCT01146938
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension
- Trial name
- NCT04488978
- Testing
- Irbesartan/Amlodipine
- Where
- South Korea
- Volunteers
- 440 people
- Sponsor
- Handok Inc.
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension
The primary objective of this study is to investigate incremental cost effectiveness of Nifedipine CR and Amlodipine in combination therapy with Valsartan for the treatment of essential hypertensive patients.
- Trial name
- NCT01518855
- Testing
- Nifedipine (Adalat, BAYA1040), Amlodipine (Norvasc), Diovan
- Where
- 4 sites in Japan
- Volunteers
- 514 people
- Sponsor
- Bayer
Hypertension
Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide
This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension
- Trial name
- NCT00796159
- Testing
- Olmesartan medoxomil
- Volunteers
- 1,723 people
- Sponsor
- Pfizer
Essential Hypertension
Study of CS-3150 in Patients With Essential Hypertension
To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.
- Trial name
- ESAX-HTN (NCT02890173)
- Testing
- CS-3150, Eplerenone
- Where
- Japan
- Volunteers
- 1,001 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
- Trial name
- NCT01785472
- Testing
- LCZ696, Olmesartan
- Where
- 50 sites in China, Hong Kong and 5 more
- Volunteers
- 1,438 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, High Blood Pressure
A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension
To evaluate the safety and effectiveness of the ROX Coupler used to create an arteriovenous anastomosis in the iliac region (between the iliac artery and vein) in subjects with hypertension.
- Trial name
- CONTROL HTN-2 (NCT02895386)
- Testing
- ROX Coupler
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- ROX Medical, Inc.